Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli63
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males59
Biosimilars and access to biologic therapy in immune-mediated diseases55
The endosomal-lysosomal system in ADC design and cancer therapy53
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?40
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases38
Antibody drug conjugates for glioblastoma: current progress towards clinical use35
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions35
Aflibercept biosimilars – so near, yet so far32
Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab31
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?30
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma29
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?29
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas29
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)27
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials27
Correction27
Signaling new therapeutic opportunities: cytokines in prostate cancer26
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era25
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway23
Long-acting delivery and therapies for neovascular age-related macular degeneration22
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden22
0.56133389472961